Leg function after radiotherapy for Ewing's sarcoma

Cancer. 1981 Mar 15;47(6):1267-78. doi: 10.1002/1097-0142(19810315)47:6<1267::aid-cncr2820470607>3.0.co;2-#.

Abstract

Twenty-nine patients with Ewing's sarcoma of the lower extremity who survived for two or more years following therapy (5000 rad locally and systemic chemotherapy) were studied to assess functional status of the affected leg. Twenty-two of twenty-nine were alive and were reexamined; the deceased patients were evaluated by record review. Twenty-two of the twenty-nine had serial radiographs, which were reviewed to assess growth change induced by radiation. The living patients were divided on the basis of clinical examination into four functional groups with Group I comprising patients with minor functional limitations and leg length discrepancy 1.5 cm or less. Group II patients had moderate functional limitations with 2.5-cm leg-length discrepancy or less. Group III patients had severe functional limitations with up to 4-cm leg length discrepancy. Group IV patients had severe complications, sufficient enough to warrant amputation. Thirteen of twenty-two patients were classified as functional Group I, five as Group II, three as Group III, and one as Group IV. Radiographic changes in growing bone did not correlate with functional results. Although a femoral fracture and an age less than 16 years at diagnosis were found to be less favorable prognostic factors for the functional treatment result, these results show that neither femoral location nor young age justify primary amputation for Ewing's sarcoma of the lower leg extremity.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Antineoplastic Agents / therapeutic use
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / physiopathology
  • Bone Neoplasms / radiotherapy*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Leg*
  • Male
  • Radiotherapy Dosage
  • Sarcoma, Ewing / drug therapy
  • Sarcoma, Ewing / physiopathology
  • Sarcoma, Ewing / radiotherapy*

Substances

  • Antineoplastic Agents